Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.

× No keyword cloud information.

14 in total

Review 1. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal: Thyroid Date: 2015-06 Impact factor: 6.568

2. Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.

Authors: Pedro Marques; Margarida da Silva Vieira; Maria João Bugalho
Journal: Endocrine Date: 2014-07-15 Impact factor: 3.633

3. Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing's syndrome in medullary thyroid carcinoma.

Authors: Marine Sitbon; Porhuoy Chou; Seydou Bengaly; Brigitte Poirot; Marie Laloi-Michelin; Laure Deville; Atanas Pachev; Ahouefa Kowo-Bille; Clement Dumont; Cécile N Chougnet
Journal: Eur Thyroid J Date: 2022-09-28

4. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958

5. Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.

Authors: A A Nella; M B Lodish; E Fox; F M Balis; M M Quezado; P O Whitcomb; J Derdak; E Kebebew; B C Widemann; C A Stratakis
Journal: J Clin Endocrinol Metab Date: 2014-03-11 Impact factor: 5.958

6. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.

Authors: Maria E Cabanillas; Mimi I Hu; Camilo Jimenez
Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958

7. Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentration.

Authors: Muhammad M Hammami; Najla Duaiji; Ghazi Mutairi; Sabah Aklabi; Nasser Qattan; Mohei El-Din M Abouzied; Mohamed W Sous
Journal: BMC Cancer Date: 2015-09-09 Impact factor: 4.430

8. Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient.

Authors: Hashem Bseiso; Naama Lev-Cohain; David J Gross; Simona Grozinsky-Glasberg
Journal: Endocrinol Diabetes Metab Case Rep Date: 2016-10-24

9. Ectopic ACTH Production Leading to Diagnosis of Underlying Medullary Thyroid Carcinoma.

Authors: Leslee N Matheny; Jessica R Wilson; Howard B A Baum
Journal: J Investig Med High Impact Case Rep Date: 2016-04-08

10. ACTH-secreting medullary thyroid cancer: a case series.

Authors: Ayanthi A Wijewardene; Sarah J Glastras; Diana L Learoyd; Bruce G Robinson; Venessa H M Tsang
Journal: Endocrinol Diabetes Metab Case Rep Date: 2017-05-17